#None #Trinity Capital #Cagent Vascular #Serranator

Trinity Capital Inc. Invests $15 Million in Cagent Vascular Inc.

In a significant move that underscores its commitment to advancing medical technology, Trinity Capital Inc. has allocated $15 million in growth capital to Cagent Vascular Inc. This infusion of cash will not only aid Cagent Vascular in scaling its operations but will also promote the innovation of its flagship product, the Serranator®, which is designed to enhance vascular procedures, specifically in the context of angioplasty.

Understanding the Investment

Trinity Capital, listed on NASDAQ under the ticker TRIN, is known for its role as a prominent alternative asset manager, focusing on providing investors with reliable returns through the private credit market. The recent funding will complement an earlier equity financing round of $45 million led by US Venture Partners in 2024. Supported by this capital, Cagent Vascular is positioned to expand its range of advanced solutions aimed at improving clinical outcomes for patients with peripheral artery disease.

Ryan Kaeding, Managing Director of Life Sciences at Trinity Capital, expressed enthusiasm about the partnership, emphasizing the importance of Cagent Vascular's innovations for healthcare professionals treating patients with vascular conditions. This collaboration aims to not only optimize existing treatments but also facilitate a major leap forward in medical interventions targeting vascular-related ailments.

Cagent Vascular’s Innovative Approach

Cagent Vascular is at the forefront of technological advancements in vascular treatment. Their Serranator® product is a game-changer in the realm of endovascular interventions, with its unique serration technology offering improved outcomes for angioplasty procedures. Unlike traditional methods, the Serranator provides enhanced predictability and control during catheter navigation, resulting in better lumen gain while significantly minimizing dissection and vessel recoil.

According to Brian Walsh, Chairman and CEO of Cagent Vascular, the Serranator® has already been utilized in over 20,000 procedures, building a robust foundation of clinical evidence that speaks to its efficacy and reliability. The additional funding from Trinity Capital is expected to accelerate clinical adoption and expand their commercial activities, ultimately pushing for an increased market presence.

A Collaborative Future

This partnership represents a pivotal moment in the healthcare sector, merging the financial expertise of Trinity Capital with the medical innovations of Cagent Vascular. The commitment to ongoing research and enhancement of their product offerings demonstrates a mutual dedication to advancing patient care and outcomes in a medically significant field.

As the healthcare landscape continues to evolve, investments like the one made by Trinity Capital signify a broader trend towards collaboration between investment firms and healthcare innovators. This synergy not only bolsters the commercial viability of groundbreaking medical technologies but also plays a crucial role in improving clinical practices and patient outcomes on a global scale.

For more information on how Trinity Capital is changing the landscape of healthcare investment, visit their website, and to keep updated on Cagent Vascular's advancements in vascular treatments, explore their online resources.

Conclusion

Trinity Capital's collaboration with Cagent Vascular heralds a new chapter in the development of medical technology tailored to enhance patient care in impactful ways. It exemplifies how strategic investments can empower companies that are pioneering advancements in essential medical fields.

• ---

For more detailed insights, follow Trinity Capital on LinkedIn and X.